In addition to hypoglycemia, SGLT2 inhibitors have many other effects, such as weight loss, lipid regulation, antihypertensive effects, lowered uric acid, improvement of non-alcoholic fatty liver disease, improvement of insulin resistance, and cardio-cerebrovascular and renal protection [32]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.